ArticleJournal of global health2025
Risk factors for severe COVID-19 outcomes in LATAM countries in the post-vaccination era: an analysis of national surveillance data in Argentina, Brazil, Colombia, and Mexico.
Article in Journal of global health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Immune response to and virological profile of SARS-CoV-2 before and after symptom onset in individuals vaccinated with inactivated COVID-19 vaccines.Human vaccines & immunotherapeutics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Identifying cases at higher risk for severe COVID-19 outcomes is essential for tailoring interventions for prevention and treatment. We aimed to determine the factors related to hospitalisation, intensive care unit (ICU) admission, use of ventilatory support, and mortality in four Latin American countries. Methods: We conducted a retrospective study using national COVID-19 surveillance databases from Argentina, Brazil, Colombia, and Mexico, covering the period from January 2021 to December 2022. We used multivariate logistic regression models to identify factors associated with hospitalisation, ICU admission, ventilatory support, and death, adjusting for confounding variables. Results: We included 34 955 384 confirmed cases in the analysis. Age and sex were significantly associated with increased odds of all outcomes. For hospitalisation, in cases aged >85 years, the odds ratio (OR) for hospitalisation ranged from 26.46 (95% confidence interval (CI) = 25.67-27.28) in Mexico to 2763.87 (95% CI = 2644.40-2888.73) in Brazil, and for males, it ranged from 1.42 (95% CI = 1.41-1.43) in Colombia to 1.77 (95% CI = 1.76-1.78) in Brazil. Indigenous race was significantly associated with higher odds of hospitalisation (ORs ranging from 1.26 to 1.98) and death (ORs ranging from 1.05 to 1.84). The number of comorbidities reported was related to increased odds of severe outcomes and varied across countries. The odds of death for cases with zero vaccine doses were significantly higher (ORs ranging from 1.72 to 31.73) compared to cases with two doses. Similarly, the odds of death for cases with one dose were significantly higher (ORs ranging from 1.73 to 7.00) compared to cases with two doses. Conclusions: Even in a post-vaccine implementation scenario, individual factors such as age, gender, comorbidities, and race still pose a risk to severe COVID-19, which demands tailoring public health strategies for prevention and treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.